Compare Citius Pharmaceuticals Inc (CTXR) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs LyondellBasell Industries NV — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while LyondellBasell Industries NV trades at $57.71 (market cap $18.90B). The key difference: LyondellBasell Industries NV is far larger — about 1291× Citius Pharmaceuticals Inc's market cap, and LyondellBasell Industries NV pays a 7.04% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | LYB | |
|---|---|---|
Market Cap | $14.64M | $18.90B |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $82.38 |
52-Week Low | $0.53 | $42.28 |
Enterprise Value | $10.86M | $30.52B |
Dividend Yield | — | 7.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
LyondellBasell (LYB) trades at $58.32, up 3.49% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported mixed earnings, beating estimates in Q1 2026 but missing in Q4 2025, while revenue has declined from $50.5B in 2022 to $30.2B in 2025. Recent news highlights partnerships for sustainable packaging and upcoming Q2 2026 results. Despite negative net income margins and ROE, LYB maintains positive operating cash flow and a dividend payout.
LYB presents a cautious opportunity with analyst consensus leaning toward Buy (43.59%) and a $73.11 price target, suggesting 25% upside. Risks include persistent revenue declines, elevated debt, and industry headwinds, but cost-cutting and focus on high-margin polymers offer potential recovery. Investors should weigh the bullish technicals and analyst optimism against fundamental challenges in the chemical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
